2022 Volume 34 Issue 1 Pages 38-43
Rheumatoid arthritis（RA）is one of most common autoimmune diseases with multifactorial etiology. With the advent of molecular-targeted drugs, complete suppression of disease has become a realistic goal. For that purpose, early diagnosis and appropriate treatment selection based on the pathological status of the individual patient are important. Genome-wide association studies have identified more than a hundred disease risk loci, and it is expected that the pathophysiology of patients at the onset stage can be evaluated by utilizing these genetic factors. In this review, I will discuss whether 1）HLA-DRB1 polymorphism, which is the largest genetic factor in RA, and 2）polygenic risk score（PRS）, which evaluates the accumulation of genetic factors, can be used for pathological evaluation around disease onset.
